Viking Therapeutics reported a second-quarter loss of $-1.10 per share, better than the $-1.27 expected. The company is advancing its clinical programs, indicating potential for future growth despite recent stock declines.
Key Highlights
- Viking Therapeutics reported a Q2 loss of $-1.10, beating the consensus estimate of $-1.27.
- The company's latest financial position includes a strong cash balance of $502 million.
- VKTX has fully enrolled two Phase 3 trials for VK2735 in obesity, aiming for significant weight loss outcomes.
- Shares of VKTX have declined by 5.6% year-to-date and 15.5% over the past month.
Viking Therapeutics, Inc. (NASDAQ: VKTX) reported an earnings per share loss of $-1.10. This figure is an improvement over the consensus estimate of $-1.27 and indicates that the company is slightly better positioned than analysts had anticipated. The reported EPS reflects continued investment in its clinical pipeline, particularly focusing on obesity treatment, an area where Viking is expanding its reach with VK2735.
This positive variance in earnings is critical, as it positions the company favorably against a backdrop of increasing interest in obesity management therapeutics.
Advancements in Clinical Trials
Viking Therapeutics has made substantial progress in its Phase 3 clinical trials for VK2735, which targets obesity. The VANQUISH-1 and VANQUISH-2 trials are fully enrolled, with participation from approximately 4,500 and 1,000 patients, respectively. This extensive participation demonstrates significant engagement and confidence in the potential effectiveness of VK2735.
As the trials move forward, they will measure weight loss percentage changes among those receiving treatment versus a placebo, a critical metric for determining the compound's efficacy and market viability.
Current Market Context
Shares of Viking Therapeutics have faced volatility lately, down 5.6% year-to-date and 15.5% in the past month, with current market capitalization at approximately $3.9 billion. The stock's performance is a reflection of broader concerns in the biopharmaceutical sector about regulatory hurdles and competitive pressures in the obesity treatment market. Adding to this, the stock experiences a short interest of 20%, indicating a notable portion of investors betting against its price, creating a challenging environment for the company.
Despite recent declines in share price, the organization’s investments in clinical development, evidenced by a strong cash position of $502 million, suggest potential resilience and opportunity for recovery.
Future Milestones to Observe
Looking ahead, Viking Therapeutics plans to initiate Phase 3 trials for an oral formulation of VK2735 in the fourth quarter, which could set a new standard in obesity treatment by being the first dual GLP-1/GIP oral agonist to market. This differentiation may position VK2735 advantageously for both patient and prescriber preference, as it expands treatment options beyond injections. Results from ongoing maintenance dosing studies are also expected later this quarter, which should provide valuable insights into the long-term management of weight loss.
The data collected will be critical in shaping both clinical strategy and investor sentiment going forward.
Analysis based on the Form 8-K filed 29 July 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...